Compare Sana Biotechnology Inc (SANA) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Tapestry, Inc. — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while Tapestry, Inc. trades at $113.97 (market cap $23.44B). The key difference: Tapestry, Inc. is far larger — about 22.8× Sana Biotechnology Inc's market cap, and Tapestry, Inc. pays a 1.57% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TPR | |
|---|---|---|
Market Cap | $1.03B | $23.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $164.78 |
52-Week Low | $2.68 | $98.81 |
Enterprise Value | $946.04M | $26.25B |
Dividend Yield | — | 1.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
TPR (Tapestry Inc.) is trading at $117.58, down 3.73% in the last session, with a bearish technical signal despite bullish oscillators. The company shows strong profitability with 77.82% gross margins and 19.09% net income margin, though 2025 net income declined significantly. Recent earnings have consistently beaten estimates, and analyst consensus remains strongly bullish with a $182.44 price target representing 55% upside potential.
The outlook remains positive with international growth accelerating in China and Europe, supported by a direct-to-consumer model. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation. Institutional buying activity remains strong, with BlackRock acquiring a $2.6 billion position in Q2 2026, supporting the bullish analyst sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
